Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 8, 2019January 8, 2019

Protalix BioTherapeutics Completes Enrollment for PRX-102 Phase 3 Trial

News

Protalix BioTherapeutics announced it has completed enrollment of its Phase 3 trial evaluating PRX-102 in Fabry disease patients previously treated with Shire’s Replagal (agalsidase alfa). The BRIDGE trial (NCT03018730) is an open-label switch-over study that will ... Read more

September 27, 2018September 27, 2018

Stroke Linked to Fabry Disease After Check on Patient’s Family History

News

A case study detailing a younger man admitted to a hospital for a stroke — later attributed to Fabry disease — highlights the importance of family history in diagnosing ... Read more

August 28, 2018August 28, 2018

New Diagnostic Kit Can Screen Newborns for Fabry Disease Using Single Dried Blood Sample

News

A new diagnostic tool that can screen for up to six lysosomal storage disorders, including Fabry disease, in newborns is now available in the United States. PerkinElmer, the kit’s ... Read more

June 28, 2018June 28, 2018

Diagnostic, Treatment Options for Fabry Disease Summarized in Review

News

A recent review has summarized the current diagnostic tools and available treatments for Fabry disease, highlighting the challenges and potential new avenues to improve patients’ diagnoses and clinical outcomes. ... Read more

April 26, 2018April 26, 2018

Plant-Derived Enzyme is Potential Source for Enzyme Replacement Therapy

News

An enzyme structurally similar to alpha-galactosidase A (GLA), present in a close relative of the tobacco plant, was able to rescue Fabry disease patients’ cells. These findings suggest that plant alpha-galactosidases ... Read more

March 29, 2018March 29, 2018

Galafold Approved in Japan to Treat Fabry Disease, Amicus Announces

News

Galafold (migalastat) capsules of 123 mg were approved in Japan to treat Fabry disease patients, ages 16 and older, with mutations amenable to the treatment, Amicus Therapeutics recently announced. This move ... Read more

March 8, 2018March 8, 2018

Heart Function Measurements Could Help Doctors Track Fabry Disease Progression, Study Finds

News

Measuring left heart chamber size and functioning could help doctors do a better job of tracking the progression of Fabry disease in people who also have a heart muscle ... Read more

January 25, 2018July 16, 2018

Amicus Therapeutics Files for FDA Approval of Migalastat to Treat Fabry Disease

News, Social Clips

Amicus Therapeutics recently submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational oral medicine migalastat for treatment of patients 16 years and older ... Read more